Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability and DDI Study of Olgotrelvir (STI-1558)
NCT05685719Phase 1Completed
- Sponsor
- ACEA Pharmaceuticals
- Start
- Jan 2023
- Primary completion
- Mar 2023
- Modality
- Prodrugs/Conditional Activator Small Molecules, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of olgotrelvir in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by ACEA Pharmaceuticals. Primary endpoints: Area Under the Curve from time 0 to last time point up to 3 weeks, Area Under the Curve from time 0 to infinity up to 3 weeks and 1 more. Started Jan 2023; status: completed.
02
Drugs
olgotrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05685719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05685719.